Meyka Pro banner
Predictive Oncology Inc.

Predictive Oncology Inc. Fundamental Analysis (NASDAQ: POAI)

POAI●NASDAQ
HealthcareMedical - Instruments & Supplies
$4.91
$0.29(6.28%)
U.S. Market opens in 51h 34m

Predictive Oncology Inc. Fundamental Analysis (NASDAQ: POAI)

Predictive Oncology Inc. (NASDAQ: POAI) shows weak financial fundamentals with a PE ratio of -0.13, profit margin of -14.01%, and ROE of -3.50%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position140.77%
PEG Ratio-0.01

Areas of Concern

ROE-3.50%
Operating Margin-3.65%
We analyze POAI's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -1706.6/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-1706.6/100

We analyze POAI's fundamental strength across five key dimensions:

Efficiency Score

Weak

POAI struggles to generate sufficient returns from assets.

ROA > 10%
-21.45%

Valuation Score

Excellent

POAI trades at attractive valuation levels.

PE < 25
-0.13
PEG Ratio < 2
-0.01

Growth Score

Weak

POAI faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

POAI maintains a strong and stable balance sheet.

Debt/Equity < 1
0.65
Current Ratio > 1
1.33

Profitability Score

Weak

POAI struggles to sustain strong margins.

ROE > 15%
-349.69%
Net Margin ≥ 15%
-14.01%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is POAI Expensive or Cheap?

P/E Ratio

POAI trades at -0.13 times earnings. This suggests potential undervaluation.

-0.13

PEG Ratio

When adjusting for growth, POAI's PEG of -0.01 indicates potential undervaluation.

-0.01

Price to Book

The market values Predictive Oncology Inc. at 2.27 times its book value. This may indicate undervaluation.

2.27

EV/EBITDA

Enterprise value stands at -0.72 times EBITDA. This is generally considered low.

-0.72

How Well Does POAI Make Money?

Net Profit Margin

For every $100 in sales, Predictive Oncology Inc. keeps $-14.01 as profit after all expenses.

-14.01%

Operating Margin

Core operations generate -3.65 in profit for every $100 in revenue, before interest and taxes.

-3.65%

ROE

Management delivers $-3.50 in profit for every $100 of shareholder equity.

-3.50%

ROA

Predictive Oncology Inc. generates $-21.45 in profit for every $100 in assets, demonstrating efficient asset deployment.

-21.45%

Following the Money - Real Cash Generation

Operating Cash Flow

Predictive Oncology Inc. generates strong operating cash flow of $15.68M, reflecting robust business health.

$15.68M

Free Cash Flow

Predictive Oncology Inc. generates strong free cash flow of $7.45M, providing ample flexibility for dividends, buybacks, or growth.

$7.45M

FCF Per Share

Each share generates $10.26 in free cash annually.

$10.26

FCF Yield

POAI converts 61.48% of its market value into free cash.

61.48%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-0.13

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.01

vs 25 benchmark

P/B Ratio

Price to book value ratio

2.27

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.34

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.65

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.33

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-3.50

vs 25 benchmark

ROA

Return on assets percentage

-0.21

vs 25 benchmark

ROCE

Return on capital employed

-0.07

vs 25 benchmark

How POAI Stacks Against Its Sector Peers

MetricPOAI ValueSector AveragePerformance
P/E Ratio-0.1330.24 Better (Cheaper)
ROE-349.69%540.00% Weak
Net Margin-1401.02%-2322.00% (disorted) Weak
Debt/Equity0.650.08 Weak (High Leverage)
Current Ratio1.335.59 Neutral
ROA-21.45%-17516.00% (disorted) Weak

POAI outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Predictive Oncology Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ